Sandra Mangiapane
Overview
Explore the profile of Sandra Mangiapane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mangiapane S, Czihal T, von Stillfried D
Dtsch Arztebl Int
. 2022 Sep;
119(24):425-426.
PMID: 36106876
No abstract available.
2.
von Stillfried D, Mangiapane S
Inn Med (Heidelb)
. 2022 Aug;
63(9):905-913.
PMID: 35925125
Reforms of emergency and after hours care have been on the health policy agenda for years, and continue to remain there in the present government's program. In order to outline...
3.
Schulz M, Mangiapane S, Scherer M, Karagiannidis C, Czihal T
Dtsch Arztebl Int
. 2022 May;
119(10):177-178.
PMID: 35583040
No abstract available.
4.
Mangiapane S, Zhu L, Schulz M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
. 2021 Oct;
64(12):1551-1558.
PMID: 34713309
Background: The COVID-19 pandemic has greatly changed the utilization of ambulatory medical care. Studies indicate that this also includes a decrease in pediatric prevention services. Aim: The aim of the...
5.
Augustin J, Mangiapane S, Kern W
Eur J Public Health
. 2015 Mar;
25(3):397-9.
PMID: 25788474
The aim of this study was to investigate whether the previously reported regional variation in outpatient antimicrobial use density in Germany has persisted or changed over time and has been...
6.
Mangiapane S, Busse R
Dtsch Arztebl Int
. 2012 Jan;
108(50):856-62.
PMID: 22259640
Background: Current guidelines recommend using aspirin, clopidogrel, beta-blockers, statins, and angiotensin converting enzyme (ACE) inhibitors after acute myocardial infarction (AMI). Although there is evidence that patients often stop taking these...
7.
Mangiapane S, Velasco Garrido M
GMS Health Technol Assess
. 2011 Feb;
5:Doc12.
PMID: 21289899
The different actors involved in health system decision-making and regulation have to deal with the question which are valid parameters to assess the health value of health technologies.So called surrogate...
8.
Velasco Garrido M, Mangiapane S
Int J Technol Assess Health Care
. 2009 Jul;
25(3):315-22.
PMID: 19619350
Objectives: Our aim was to review the recommendations given by health technology assessment (HTA) institutions in their methodological guidelines concerning the use of surrogate outcomes in their assessments. In a...
9.
Mangiapane S, Blettner M, Schlattmann P
Pharmacoepidemiol Drug Saf
. 2007 Oct;
17(2):115-24.
PMID: 17955496
Purpose: To examine the recent epidemiological studies on aspirin use and breast cancer risk published from 2001 to 2005 within a meta-analysis, to investigate reasons for heterogeneity between the individual...
10.
Mangiapane S, Schulz M, Muhlig S, Ihle P, Schubert I, Waldmann H
Ann Pharmacother
. 2005 Oct;
39(11):1817-22.
PMID: 16219893
Background: Despite significant progress in asthma drug therapy in recent years, there has been no major change in asthma morbidity and mortality. It is still important to determine whether pharmaceutical...